Hims & Hers Health is expanding its GLP-1 weight-loss treatment offerings by partnering with Novo Nordisk to provide access to medications such as Wegovy and Ozempic, and by acquiring Eucalyptus to extend its international reach. The telehealth company is moving deeper into prescription weight management, tying its platform to widely recognized GLP-1 drugs. The Eucalyptus acquisition adds scale beyond the United States. These moves outline a new phase focused on weight loss and international markets, raising questions about revenue mix, margin profile, and regulatory exposure. The stock has risen 41.2% over the last 30 days, trading at US$33.54, which is about 22.8% above the analyst price target of US$27.32 and at a very large premium to estimated fair value.
Hims Hers Health IncExpands GLP-1 offerings through Novo Nordisk deal and Eucalyptus acquisition, driving prescription weight management growth.
Novo Nordisk A/SPartners with Hims & Hers to provide Wegovy and Ozempic, expanding distribution channel for its GLP-1 drugs.